Group 1 - The core point of the article is that Jiufang Zhitu Holdings has announced a share placement agreement with existing shareholders, selling 20 million shares at a price of HKD 39.25 per share, which represents a discount of approximately 6.0% from the last closing price of HKD 41.75 and about 17.0% from the average closing price of HKD 47.3 over the past five trading days [1][2] - Following the completion of the subscription, the company's issued share capital is expected to increase by approximately 4.27% [1] - The estimated net proceeds of approximately HKD 746 million from the subscription will be used for various strategic investments, including on-chain financial resources, digital asset exchanges, and digital asset trust banks, as well as for general corporate purposes [2] Group 2 - Jiufang Zhitu Holdings reached its highest price of HKD 54 since its listing on July 14, and has seen a cumulative increase of 854.06% compared to its lowest price of HKD 5.66 recorded on September 25, 2024, marking it as an "8-fold stock" [2]

Market Overview - Hong Kong stocks experienced a pullback after an initial rise, with the Hang Seng Index closing down 0.29% at 24,517.76 points and a total trading volume of 258.95 billion HKD [1] - The Hang Seng China Enterprises Index fell 0.18% to 8,861.39 points, while the Hang Seng Tech Index decreased by 0.24% to 5,418.4 points [1] - Shenwan Hongyuan remains optimistic about investment opportunities in Hong Kong and A-share markets, predicting that Hong Kong will play a crucial role in the restructuring of the global financial order [1] Blue Chip Performance - Anta Sports (02020) led blue-chip stocks, rising 2.28% to 91.85 HKD, contributing 4.55 points to the Hang Seng Index [2] - Other notable performers included Kuaishou-W (01024) up 2.13% and Trip.com Group-S (09961) up 1.59%, while Shenzhou International (02313) and Zhongsheng Holdings (00881) saw declines of 2.75% and 2.67%, respectively [2] Sector Highlights - Large tech stocks showed mixed results, with Kuaishou rising over 2% and Baidu nearly 1%, while Tencent fell 0.19% [3] - The humanoid robot sector is gaining traction, with Shengye rising nearly 15% following positive developments [3] - The innovative drug sector remains active, with Lijun Pharmaceutical rising 13% amid ongoing interest in new drug procurement [4][5] Innovative Drug Sector - The 11th batch of national drug procurement has started, focusing on mature "old drugs" while excluding innovative drugs [5] - Analysts believe that the current innovative drug market is driven by value reassessment, with domestic investors increasing their positions through Hong Kong Stock Connect [5] Stablecoin Activity - China San San Media (08087) surged 72.73% after announcing plans to apply for a stablecoin license in Hong Kong, which will officially take effect on August 1 [6] - The global regulatory framework for stablecoins is expected to lead to significant industry growth [6] New Consumption Trends - New consumption stocks showed varied performance, with Guoquan (02517) up 7.29% and Hu Shang Ayi (02589) up 1.99%, while Gu Ming (01364) fell 4.26% [7] - Guoquan expects a net profit of approximately 180 to 210 million RMB for the first half of 2025, representing a year-on-year increase of 111% to 146% [7] Notable Stock Movements - Weiyali (00854) saw a dramatic increase of 288.34% after resuming trading, reaching a peak of 33.2 HKD [8] - Chongqing Machinery (02722) rose 14.06% following news of NVIDIA resuming sales of its H20 chip in China [9] - Jiufang Zhitu Holdings (09636) increased by 10.06% as it plans to issue shares for strategic investments [10] - Quzhi Group (00917) fell 12.06% after announcing a share placement at a discount to its market price [11]

Group 1 - The Hang Seng Index rose by 0.28%, gaining 68 points to close at 24,658 points, while the Hang Seng Tech Index increased by 0.61% [1] - The Hong Kong stock market saw a trading volume of HKD 157.9 billion in the morning session [1] - The National Healthcare Security Administration of China added innovative commercial insurance drugs to the list for 2025, supporting new drugs with high clinical value but payment bottlenecks, leading to a rise in the Hang Seng Biotechnology Index [1] Group 2 - Livzon Pharmaceutical (01513) surged by 12.69% as the Phase II clinical trial for its cardiovascular innovative drug H001 capsule completed patient enrollment [2] - InnoCare Pharma (02577) increased by 6.41%, planning to significantly enhance its 8-inch gallium nitride wafer production capacity over the next five years [2] - China Heartland Fertilizer (01866) rose by 3.83% following reports of a meeting held by relevant authorities to ensure the supply and stabilize prices of potash fertilizer [2] Group 3 - Chongqing Machinery and Electric (02722) saw a significant increase of over 17% due to catalysts in the domestic AIDC market, with Chongqing Cummins being a supplier for engines [2] Group 4 - Jifang Zhitu Holdings (09636) rose by 10.18% after announcing a proposed share placement to raise approximately HKD 746 million for developing on-chain financial resources [3] Group 5 - Smoore International (06969) fell by 3.55%, expecting a year-on-year decline of approximately 21% to 35% in half-year profits [4] - Kanglong Chemical (03759) issued a profit warning, dropping by 5.24%, with an expected year-on-year decline of 36% to 39% in net profit attributable to shareholders for the first half [5]

Group 1 - The company, Jiufang Zhitu Holdings, announced a placement and subscription agreement on July 16, 2025, involving the sale of 20 million shares at a price of HKD 39.25 per share, which represents approximately 4.46% of the existing issued share capital as of the announcement date [1] - The subscription price of HKD 39.25 per share reflects a discount of about 6.0% compared to the last closing price of HKD 41.75, and a discount of approximately 17.0% and 15.3% compared to the average closing prices over the last 5 and 10 trading days, respectively [2] Group 2 - The estimated net proceeds of approximately HKD 746 million from the subscription will be used for various strategic initiatives, including developing on-chain financial resources, strategic investments in RWA underlying assets, digital asset exchanges, digital asset trust banks, and stablecoin operators [2] - The company aims to enhance its position in the digital financial ecosystem by focusing on digital asset services in Hong Kong and overseas regions, including the Middle East, and developing a digital asset investment service targeting retail clients [2] - The company plans to explore new models for digital asset investment advisory, leveraging AI and research, and utilizing its experience in MCN operations to drive innovation and development in on-chain finance [2]

不得在美國分發 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並非在美國或任何其他司法權區出售或收購證券的邀請或要約或招攬購買證 券的要約，未根據任何該等司法權區的證券法登記或獲批准而於上述司法權區進行的相關邀 請、要約、收購、招攬或出售均屬違法。 本公告及其內容並非任何合約或承諾的根據。本公告及其任何副本不得帶入美國或在美國傳 閱。本公告所述證券並無亦不會根據1933年美國證券法（經修訂）或向美國任何州或其他司法權 區的任何證券監管機構登記，且不會在美國提呈發售或出售，惟獲得1933年美國證券法（經修 訂）及相關州或地方證券法登記規定的適用豁免，或屬不受1933年美國證券法（經修訂）及相關 州或地方證券法登記規定約束的交易則除外。於美國公開發售的任何證券將以招股章程形式進 行，有關招股章程可向本公司索取，並將載有關於本公司及管理層的詳細資料以及財務報表。 本公司不會在美國公開發售證券。 JF SmartInvest Holdings ...

Investment Rating - The report assigns a "Buy" rating for Jiufang Zhitu Holdings (9636.HK) based on its strong performance and growth potential in the market [9]. Core Views - Jiufang Zhitu's H1 2025 performance exceeded expectations, with projected net profit for shareholders between RMB 830 million and RMB 870 million, and revenue expected to reach approximately RMB 2.1 billion, marking a year-on-year increase of about RMB 1.202 billion [1]. - The company is leveraging its AI capabilities through the integration of its large model with a comprehensive financial knowledge base, which is expected to enhance its service offerings and customer base [1]. - The planned acquisition of Yintech Financial aims to expand into overseas markets and diversify its business portfolio, potentially reducing risks associated with market concentration [1]. Financial Summary - For 2024, the company reported revenue of RMB 2,306 million, with projections of RMB 3,512 million for 2025, representing a growth rate of 52% [3]. - The net profit attributable to shareholders is expected to rise significantly from RMB 272 million in 2024 to RMB 1,211 million in 2025, reflecting a growth rate of 344% [3]. - Earnings per share (EPS) are forecasted to increase from RMB 0.61 in 2024 to RMB 2.70 in 2025 [3]. Financial Projections - The financial outlook for Jiufang Zhitu indicates a steady increase in revenue and profit over the next few years, with expected revenues of RMB 4,056 million in 2026 and RMB 4,681 million in 2027 [4]. - The company is projected to maintain a strong gross margin, with estimates of 89.24% in 2025 and 88.34% in 2026 [4]. - The return on equity (ROE) is expected to be 43.14% in 2025, indicating strong profitability relative to shareholder equity [4].

Core Viewpoint - Jiufang Zhitu Holdings (09636.HK) experienced a significant stock price drop of 10.98% after a strong opening, raising concerns among investors despite a substantial increase in its stock price over the past year [2][7]. Financial Performance - The company announced a profit forecast for the first half of the year, expecting a net profit attributable to shareholders between 830 million and 870 million RMB, a turnaround from a loss of 174 million RMB in the same period last year [4]. - Revenue for the first half is projected to be approximately 2.1 billion RMB, representing an increase of 1.202 billion RMB compared to the previous year [4]. - The surge in revenue and profit is attributed to the strong sales of the company's investor education products, with expected order amounts reaching 1.703 billion RMB, an increase of 772 million RMB year-on-year [5]. Market Context - Jiufang Zhitu Holdings operates in a sector closely tied to the performance of capital markets, which have been active since September 2022, contributing to the company's significant performance improvement [5][6]. - The overall market environment has seen increased trading activity, with the Shanghai Composite Index reaching 3,500 points, leading to heightened investor confidence and demand for the company's products and services [6][7]. Investor Sentiment and Risks - Despite the positive financial outlook, investor sentiment turned negative, leading to a sell-off as concerns about the sustainability of the stock's high valuation emerged, with a dynamic P/E ratio of approximately 70, higher than industry peers [7]. - The company's reliance on live-stream marketing has raised compliance concerns, especially after regulatory scrutiny regarding "illegal stock recommendations" [7]. - There are reports of user complaints regarding misleading marketing practices, which have contributed to a trust crisis for the company, raising questions about its future ability to regain investor confidence [7].

Summary of Key Points Core Viewpoint - As of July 14, a total of 138 stocks reached their 52-week highs, indicating a strong performance in the market, with notable leaders including Green Heart Group Holdings, OK Blockchain, and Pearl River Steel Pipe [1]. Group 1: Top Performers - Green Heart Group Holdings (02999) achieved a closing price of 0.013 with a peak of 0.017, marking a 70.00% increase [1]. - OK Blockchain (01499) closed at 0.680, reaching a high of 0.690, reflecting a 48.39% rise [1]. - Pearl River Steel Pipe (01938) had a closing price of 0.335 and a peak of 0.340, resulting in a 33.33% increase [1]. Group 2: Other Notable Stocks - Weishi Jiajie (00856) saw a 32.01% increase, closing at 8.870 with a high of 11.300 [1]. - Cloud Intelligence (09678) reached a high of 520.000, closing at 510.000, which is a 20.99% increase [1]. - China Chengtong Development Group (00217) closed at 0.165 with a peak of 0.166, marking a 14.48% rise [1]. Group 3: Additional Stocks with Significant Increases - Sihuan Pharmaceutical (00460) closed at 1.380, reaching a high of 1.430, which is a 14.40% increase [1]. - Taited Pharmaceutical (03880) had a closing price of 36.950 and a peak of 37.400, reflecting a 13.85% rise [1]. - Beihai Kangcheng-B (01228) closed at 0.850 with a high of 0.960, resulting in a 12.94% increase [1].

本公告乃由九方智投控股有限公司（「本公司」，連同其附屬公司，統稱「本集團」） 根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)條以及香港 法例第571章證券及期貨條例第XIVA部項下之內幕消息條文（定義見上市規則）而 作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 JF SmartInvest Holdings Ltd 九方智投控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：9636） 正面盈利預告 本公司股東及潛在投資者於買賣本公司股份時務請審慎行事，並應注意過度依賴 或使用上述資料可能引致投資風險。 承董事會命 九方智投控股有限公司 董事會主席 陳文彬 中國香港，2025年7月13日 截至本公告日期，執行董事為陳文彬先生、陳冀庚先生及張培紅先生，非執行董 事為嚴明先生及CHEN NINGFENG女士，以及獨立非執行董事為趙國慶博士、范 勇宏先生及田舒先生。 2 本公司董事（「董事」）會（「董事會」）謹此知 ...

Group 1 - The company announced a dividend plan based on the 2024 annual report, distributing HKD 0.33 per share, totaling approximately HKD 148 million, with a payout ratio of 50.3% [1] - In 2024, the company achieved a net profit attributable to shareholders of approximately RMB 272 million, a year-on-year increase of 42.8%, and revenue of approximately RMB 2.306 billion, a year-on-year increase of 17.3% [1] - The total order amount for 2024 reached approximately RMB 3.506 billion, a year-on-year increase of 49.3%, with the number of paying users reaching 181,500, a year-on-year increase of approximately 149.4% [1] Group 2 - The company continued to deepen its investment in technology research and development, with R&D expenditure of approximately RMB 319 million in 2024, a year-on-year increase of 10.9%, accounting for about 13.8% of total revenue [2] - Under the "technology + R&D" dual-drive strategy, the company launched the industry's first stock learning product "Yizhi Gudao" and several AI investment advisory products [2] - The company aims to deepen the application of AI technology in investment advisory services, promoting a "digital intelligence" transformation and building an intelligent investment advisory ecosystem [2]